Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 692 | 18% |
| 2020 | 8 | 545 | 22% |
| 2021 | 11 | 572 | 27% |
| 2022 | 13 | 726 | 31% |
| 2023 | 21 | 778 | 35% |
| 2024 | 19 | 940 | 37% |
| 2025 from claims | – | 954 771–1,120 | 37% |
| 2026 forecast | – | 1,038 813–1,303 | 37% |
| 2027 forecast | – | 1,122 832–1,483 | 37% |
| 2028 forecast | – | 1,213 859–1,674 | 38% |
| 2029 forecast | – | 1,311 891–1,880 | 38% |
| 2030 forecast | – | 1,418 929–2,104 | 38% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 78% of the cases CMS names in Nebraska; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 12% inpatient hospital, 88% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,000 | ~120 | ~920 |
| 2027 · ~1,100 | ~120 | ~1,000 |
| 2028 · ~1,200 | ~130 | ~1,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 11% (12% in 2025), hospital outpatient about 89% (88% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 82 | 5,581+11%/yr | +11%/yr | 4.1 | 0% | 10,800 in 2030+12%/yr |
| Ohio | 65 | 3,959+2.2%/yr | +2.2%/yr | 3.6 | 0% | 6,330 in 2030+8.1%/yr |
| Indiana | 44 | 2,775+5.4%/yr | +5.4%/yr | 4.0 | 0% | 4,650 in 2030+9%/yr |
| Michigan | 41 | 2,711−0.1%/yr | −0.1%/yr | 3.3 | 0% | 4,390 in 2030+8.4%/yr |
| Missouri | 36 | 2,414−2.3%/yr | −2.3%/yr | 3.9 | 2% | 2,900 in 2030+3.1%/yr |
| Wisconsin | 40 | 2,262+6.8%/yr | +6.8%/yr | 4.1 | 1% | 4,120 in 2030+11%/yr |
| Minnesota | 28 | 1,774+6.4%/yr | +6.4%/yr | 4.0 | 0% | 3,640 in 2030+13%/yr |
| Kansas | 20 | 1,248+4.7%/yr | +4.7%/yr | 3.1 | 0% | 2,190 in 2030+9.8%/yr |
| Iowa | 25 | 1,181+6.7%/yr | +6.7%/yr | 2.7 | 0% | 2,360 in 2030+12%/yr |
| North Dakota | 6 | 329+11%/yr | +11%/yr | 3.3 | 0% | 750 in 2030+15%/yr |
| South Dakota | 8 | 310+7.1%/yr | +7.1%/yr | 2.4 | 0% | 620 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 135 | 27,462−1.7%/yr | −1.7%/yr | 108.20.9× | 51% | 28,600 in 2030+0.7%/yr |
| ERCP & endoscopic ultrasound | 11 | 985−1.3%/yr | −1.3%/yr | 3.81.0× | 3% | 1,130 in 2030+2.4%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
Stryker leads with 36% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 11 companies reported engagement with Nebraska’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products, about $991 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.